| 王 盟,张秀芹,杨 静,林文娟,汪允嘉,林文静.纳洛酮对慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者血清炎症因子水平及血气分析的影响[J].现代生物医学进展英文版,2017,17(20):3936-3939. |
| 纳洛酮对慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者血清炎症因子水平及血气分析的影响 |
| Effects of Naloxone on Inflammatory Factors and Blood Gas Analysis of Patients with Chronic Obstructive Pulmonary Disease and Type Ⅱ Respiratory Failure |
| Received:December 28, 2016 Revised:January 24, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.20.032 |
| 中文关键词: 纳络酮 慢性肺阻塞性肺病 Ⅱ型呼吸衰竭 炎性因子 血气分析 |
| 英文关键词: Naloxone Chronic obstructive pulmonary disease TypeⅡrespiratory failure Inflammatory factors Blood gas analysis |
| 基金项目:陕西省科学技术攻关项目（98K12-G18） |
|
| Hits: 300 |
| Download times: 200 |
| 中文摘要: |
| 摘要 目的：分析纳洛酮对慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者血清炎症介质水平及血气分析的影响。方法：将106例慢性阻塞性肺疾病并Ⅱ型呼吸衰竭患者按抽签法分作对照组与研究组，各53例，对照组行常规治疗，研究组基于对照组加以纳络酮治疗。比较两组肺总量（TLC）、第1秒末用力呼气量（FEV1）、最大口腔呼气压（PEMAX），血氧饱和度（SaO2）、动脉血氧分压（PaO2）、二氧化碳分压（PaCO2），最大氧耗量（VO2）、氧摄取率（ERO2），白细胞介素-10、18（IL-10、IL-18），肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP），谷胱甘肽过氧化物酶（GSH-Px）、超氧化物歧化酶（SOD）、脂质过氧化物（LPO），不良反应。结果：治疗后，研究组TLC、FEV1、PEMAX、SaO2、PaO2、CaO2、IL-10、GSH-Px、SOD均高于对照组，组间差异有统计学意义（P<0.05）。研究组PaCO2、VO2、ERO2、IL-18、TNF-α、CRP、LPO均低于对照组（P<0.05）。两组不良反应比较无差异（P>0.05）。结论：纳络酮可降低慢性阻塞性肺疾病并Ⅱ型呼吸衰竭的炎症介质，改善血气分析指标。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the influence of naloxone on inflammatory factors and blood gas analysis of patients with chronic obstructive pulmonary diseasecopd (COPD) and type Ⅱ respiratory failure. Methods: 106 patients with COPD and type Ⅱ respiratory failure were selected and randomly divided into the control group and the research group with 53 cases in each group. The patients in the control group were treated with the conventional method, while the patients in the research group were treated with naloxone on the basis of the control group. Then the TLC, forced expiratory volume at the end of 1 second (FEV1), maximal oral expiratory pressure (PEMAX), blood oxygen saturation (SaO2), arterial blood oxygen partial pressure (PaO2), CO2 partial pressure (PaCO2), maximum oxygen consumption (VO2), oxygen uptake rate (ERO2), IL-10, IL-18, tumor necrosis factor-α (TNF-α), c-reactive protein (CRP), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), lipid peroxide (LPO) and adverse reactions between two groups were observed and compared before and after the treatment. Results: After treatment, the TLC, FEV1, PEMAX, SaO2, PaO2, CaO2, IL-10, GSH-Px and SOD in the research group were higher than those of the control group, and the differences were statistically significant (P<0.05). The PaCO2, VO2, ERO2, IL-18, TNF-α, CRP and LPO in the research group were lower than those of the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference on the adverse reactions between the two groups (P>0.05). Conclusion: Naloxone in the treatment of COPD and type Ⅱ respiratory failure can reduce inflammatory mediators, improve the blood gas analysis index. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
